stockrow
Friday 6 November 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
- EPS
- +58.7%
- Free cash flow
- −24.3%
Quarter to June 2026, against a year earlier
4.26
0.02
+0.47%
Follow CING
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.16 | 2.55 | 0.06 | 1.12 | 16.05 | 0.53 | 0.33 | — |
Net Debt/EBITDA |
0.51 | 0.65 | 0.00 | 0.31 | 0.82 | 0.18 | (0.16) | — |
Debt/Assets |
7.64% | 16.39% | 0.13% | 0.19% | 0.16% | 0.91% | 42.51% | 0.00% |
Debt/Equity |
0.46 | 0.33 | 0.00 | 0.01 | 0.00 | 0.04 | 3.65 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.77 | 1.11 | 0.64 | 0.90 | 0.50 | 0.95 | 0.76 | — |
Capex/Depreciation |
(0.29) | (0.32) | (0.38) | (0.39) | (1.15) | (0.60) | 0.00 | — |
| (450.60%) | (5,650.78%) | 1,575.62% | (142.98%) | (187.12%) | (752.88%) | (1,210.11%) | — | |
| (149.98%) | (180.43%) | (315.98%) | (103.09%) | (144.45%) | (129.80%) | (437.29%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (294.59%) | (3,023.99%) | 0.00% | — |
Return on Tangible Assets |
(656.12%) | (169.09%) | 331.42% | (469.90%) | (99.32%) | (489.51%) | (528.07%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(3.44) | (12.24) | (203.45) | (319.45) | (364.00) | (12.76) | (8.34) | — |
Cash per Share |
2.17 | 8.01 | 0.70 | 106.70 | 533.78 | 2.12 | 0.41 | — |
Shareholders Equity per Share |
0.50 | 4.89 | (91.59) | 77.33 | 674.55 | 2.29 | 0.58 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.50 | 4.89 | (91.59) | 77.33 | 674.55 | 2.29 | 0.58 | — |
Free Cash Flow |
(17.41) | (18.66) | (15.26) | (16.04) | (11.25) | (7.21) | (8.81) | — |
Working Capital |
1.70 | 7.69 | (9.65) | 0.86 | 17.71 | (1.57) | (1.97) | — |
Capital Expenditures |
(0.16) | (0.21) | (0.22) | (0.15) | (0.81) | (0.40) | (1.02) | — |
Net Current Asset Value |
(0.56) | 5.25 | (9.78) | 0.35 | 16.84 | (2.71) | (3.69) | — |
| Other line items | ||||||||
Quick Ratio |
1.06 | 2.46 | 0.01 | 0.80 | 14.60 | 0.40 | 0.19 | — |
Depreciation/Fixed assets |
0.33 | 0.31 | 0.23 | 0.14 | 0.23 | 0.22 | 0.04 | — |
Cash ROIC |
(119.12%) | (84.43%) | 223.98% | (173.18%) | (30.09%) | (283.58%) | (267.03%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,868.10 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.41) | (12.10) | (200.46) | (316.39) | (337.63) | (12.04) | (8.34) | — |
Capex per Share |
(0.03) | (0.14) | (2.99) | (3.06) | (26.37) | (0.71) | 0.00 | — |
Average Receivables |
0.02 | 0.02 | 0.12 | 0.46 | 0.42 | 0.13 | 0.13 | — |
Average Payables |
1.65 | 3.23 | 2.98 | 0.51 | 0.62 | 1.44 | 1.44 | — |
Average Assets |
14.97 | 9.18 | 7.45 | 17.15 | 14.34 | 5.53 | 2.64 | — |
Average Common Equity |
4.98 | 0.29 | (1.49) | 12.36 | 11.07 | 0.95 | 0.95 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026